GlassScriptPhysician profile
Desiree B Thomas
NPI 1821095258
$20,034.12
in general payments reported to CMS, 2019-2025
22 companies · $8,743 in 2025
The $8,743 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $201 · 2021: $485 · 2022: $7,313 · 2023: $896 · 2024: $1,592 · 2025: $8,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,400 · Food and Beverage: $1,438 · Travel and Lodging: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,400.00 |
| Food and Beverage | $1,437.97 |
| Travel and Lodging | $392.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $8,200.00 | 2025 | Kisunla |
| Eli Lilly and Company | $6,840.93 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $900.00 | 2024 | Rytary |
| Novartis Pharmaceuticals Corporation | $718.98 | 2019-2023 | |
| Abbvie INC. | $646.55 | 2021-2024 | Botox |
| Biogen, INC. | $400.18 | 2021-2025 | Tysabri |
| Sk Life Science, INC. | $326.77 | 2020-2024 | Xcopri |
| Acadia Pharmaceuticals INC | $271.64 | 2019-2023 | Nuplazid |
| Abbott Laboratories | $243.85 | 2022 | |
| Genzyme Corporation | $220.35 | 2019 | |
| Medtronic, INC. | $204.85 | 2022-2024 | Percept PC Brainsense |
| Celgene Corporation | $132.48 | 2021 | |
| Adamas Pharmaceuticals, INC. | $130.27 | 2019 | |
| Boston Scientific Corporation | $126.37 | 2023 | |
| Neurocrine Biosciences, INC. | $125.04 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $117.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $116.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $104.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $96.19 | 2024 | Austedo Xr |
| Emd Serono, INC. | $52.91 | 2020-2023 | |
| Allergan, INC. | $46.04 | 2019-2022 | |
| Acorda Therapeutics, INC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.